TUESDAY, Dec. 12 (HealthDay News) -- Using liposome-reconstituted recombinant factor VIII could help patients with hemophilia A cut their infusions down from every two to three days to once a week, according to a report in the Dec. 1 issue of Blood.
Jack Spira, M.D., Ph.D., of Recoly Curacao in Netherlands Antilles, and colleagues in Russia conducted a blinded, multi-center trial of recombinant factor VIII (rFVIII) reconstituted with PEGylated liposomes to reduce bleeding episodes in patients with hemophilia A.
Compared to standard rFVIII, liposome-reconstituted rFVIII extended the average number of days patients went without a bleeding episode (7.2 days and 13.3 days at the highest dose). Liposome-reconstituted rFVIII was well tolerated.
Weekly injections "would represent a major improvement in convenience, which could increase compliance, could reduce the number of bleeding episodes, and may also reduce the morbidity and improve the quality of life for the hemophilia population," the authors conclude.
Abstract
Full Text (subscription or payment may be required)
